<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">tbjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Туберкулез и социально значимые заболевания</journal-title><trans-title-group xml:lang="en"><trans-title>Tuberculosis and socially significant diseases</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2413-0346</issn><issn pub-type="epub">2413-0354</issn><publisher><publisher-name>ООО «Ин-Тренд</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.54921/2413-0346-2025-13-2-19-24</article-id><article-id custom-type="elpub" pub-id-type="custom">tbjournal-600</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭПИДЕМИОЛОГИЯ ТУБЕРКУЛЕЗА</subject></subj-group></article-categories><title-group><article-title>Особенности онкологической коморбидности у больных туберкулезом</article-title><trans-title-group xml:lang="en"><trans-title>Features of oncological comorbidity in tuberculosis patients</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зубань</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Zuban</surname><given-names>O. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зубань Олег Николаевич – заместитель директора; профессор кафедры фтизиатрии; доктор медицинских наук, профессор</p><p>107014, г. Москва, ул. Стромынка, д. 10, стр. 1 Тел. + 7 (925) 720-42-01</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">pan_zuban@msn.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Авдентова</surname><given-names>В. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Avdentova</surname><given-names>V. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Авдентова Виктория Борисовна – научный сотрудник научно-клинического отдела; ассистент кафедры фтизиатрии</p><p>107014, г. Москва, ул. Стромынка, д. 10, стр. 1 Тел. + 7 (499) 268-04-15</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">AvdentovaVB@zdrav.mos.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сикаев</surname><given-names>Ю. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Sikaev</surname><given-names>Yu. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сикаев Юнир Ринатович – врач-уролог туберкулезного внелегочного отделения Клиники № 2</p><p>107014, г. Москва, ул. Барболина, д. 3 Тел. + 7 (499) 268-27-60</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">SikaevYR@zdrav.mos.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ города Москвы «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы» ; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Research and Clinical Center for Tuberculosis Control of Moscow Government Department of Health ; Russian Medical Academy of Postgraduate Education</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ города Москвы «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Research and Clinical Center for Tuberculosis Control of Moscow Government Department of Health</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>17</day><month>10</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><fpage>19</fpage><lpage>24</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Зубань О.Н., Авдентова В.Б., Сикаев Ю.Р., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Зубань О.Н., Авдентова В.Б., Сикаев Ю.Р.</copyright-holder><copyright-holder xml:lang="en">Zuban O.N., Avdentova V.B., Sikaev Y.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.tb-journal.ru/jour/article/view/600">https://www.tb-journal.ru/jour/article/view/600</self-uri><abstract><p>Цель. Определить место и структуру злокачественных новообразований у больных туберкулезом (ТБ).Материал и методы. В ретроспективном исследовании использованы данные системы регионального эпидемиологического мониторинга ТБ, отчетных форм № 33 за 2018–2024 гг. За это время из ГБУЗ «МНПЦ борьбы с туберкулезом ДЗМ» выписано 157 больных ТБ в возрасте ≥ 18 лет с сопутствующей онкопатологией, 106 (67,5%) мужчин и 51 (32,5%) женщин.Результаты. Рак у больных туберкулезом в 2 раза чаще встречается у мужчин (67,5%), чем у женщин (32,5%); на возраст 51– 70 лет приходится 55,4% всех случаев (у мужчин – 63,2% случаев). Среди клинических форм ТБ у больных с сопутствующей онкопатологией преобладал инфильтративный (47,1%), реже – туберкулема (10,8%), диссеминированный (7,0%) и фиброзно-кавернозный ТБ (6,4%). Злокачественные новообразования чаще локализовались в мочеполовой системе (39,5%), реже в органах пищеварительной (17,8%) и дыхательной (16,4%) систем. Сочетание рака и ТБ в одной системе органов выявлено у 25 (16,6%) из 151 страдающего ТБ легких и у 2 (5,9%) из 34 – ТБ почек. У подавляющего большинства (91,1%) больных имел место активный ТБ в различных сочетаниях: туберкулез органов дыхания – у 86,6%, туберкулез внелегочной локализации – у 1,9%, сочетанный туберкулез органов дыхания и внелегочной локализации у 1,3% и активный внелегочный туберкулез с излеченным туберкулезом органов дыхания в анамнезе – у 1,3%.Заключение. Пик заболеваемости сочетанной патологией ТБ/рак приходится на возраст 51–70 лет преимущественно за счет мужчин. В структуре онкологической патологии у больных туберкулезом доминируют опухоли внелегочной локализации с преобладанием новообразований органов мочеполовой системы, пищеварения и дыхания.</p></abstract><trans-abstract xml:lang="en"><p>Aim. To determine the place and structure of malignancies in tuberculosis patients.Material and methods. The retrospective study used the data of the regional epidemiological system of TB monitoring, reporting forms № 33 for 2018–2024. During this time 157 TB patients aged ≥18 years with concomitant oncopathology were discharged from the Moscow Research and Clinical Center for Tuberculosis Control. Among them there were 106 (67.5%) men and 51 (32.5%) women.Results. Cancer in TB patients was 2-fold more common in men (67.5%) than in women (32.5%), occurring in 63.2% (67 out of 106) of cases between the ages of 51–70 years in men and in 55.4% among all patients (87 out of 157). The main clinical form of TB was infiltrative (47.1%), less frequently tuberculoma (10.8%), disseminated (7.0%) and fibrotic cavernous TB (6.4%). The genitourinary system (39.5%) was the most frequently affected by cancer processes, the organs of the digestive (17.8%) and respiratory (16.4%) systems were less frequently affected. The combination of cancer and TB in the same organ system was found in 25 (16.6%) of 151 lung TB patients and in 2 (5.9%) of 34 kidney TB patients. The overwhelming majority (91.1%) of patients had active TB in various combinations: respiratory TB in 86.6%, extrapulmonary TB in 1.9%, combined respiratory and extrapulmonary TB in 1.3%, and active extrapulmonary TB with a history of cured respiratory TB in 1.3%.Conclusion. The peak incidence of TB/cancer combined pathology is at the age of 51–70 years mainly due to men. The structure of oncological pathology in TB patients is dominated by tumors of extrapulmonary localization with predominance of neoplasms of genitourinary, digestive and respiratory organs.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>туберкулез</kwd><kwd>рак</kwd><kwd>новообразования</kwd><kwd>сочетание туберкулеза и рака</kwd></kwd-group><kwd-group xml:lang="en"><kwd>tuberculosis</kwd><kwd>cancer</kwd><kwd>neoplasms</kwd><kwd>combination of tuberculosis and cancer</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Иванова Д.А., Белиловский Е.М., Богородская Е.М. и др. Влияние сопутствующей патологии на исходы лечения больных туберкулезом // Терапевтический архив. – 2024. – Т. 96. – № 8. – C. 790-796. doi: 10.26442/00403660.2024.08.202812.</mixed-citation><mixed-citation xml:lang="en">Иванова Д.А., Белиловский Е.М., Богородская Е.М. и др. Влияние сопутствующей патологии на исходы лечения больных туберкулезом // Терапевтический архив. – 2024. – Т. 96. – № 8. – C. 790-796. doi: 10.26442/00403660.2024.08.202812.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Новицкая Т.А., Ариэль Б.М., Двораковская И.В. и др. Морфологические особенности сочетания туберкулеза и рака легких // Архив патологии. – 2021. – Т. 83. – № 2. – С. 19-24.</mixed-citation><mixed-citation xml:lang="en">Новицкая Т.А., Ариэль Б.М., Двораковская И.В. и др. Морфологические особенности сочетания туберкулеза и рака легких // Архив патологии. – 2021. – Т. 83. – № 2. – С. 19-24.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Холтобин Д.П., Кульчавеня Е.В., Хомяков, В.Т. Рак и туберкулез мочеполовой системы (обзор литературы и клиническое наблюдение) // Урология. – 2016. – № 4. – С. 106-109.</mixed-citation><mixed-citation xml:lang="en">Холтобин Д.П., Кульчавеня Е.В., Хомяков, В.Т. Рак и туберкулез мочеполовой системы (обзор литературы и клиническое наблюдение) // Урология. – 2016. – № 4. – С. 106-109.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Эпидемиология, профилактика и лечение туберкулеза в г. Москве, 2022 г. / Под ред. Е.М. Богородской. – М.: МНПЦБТ, 2023. – 294 с.</mixed-citation><mixed-citation xml:lang="en">Эпидемиология, профилактика и лечение туберкулеза в г. Москве, 2022 г. / Под ред. Е.М. Богородской. – М.: МНПЦБТ, 2023. – 294 с.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Basham C.A., Smith S.J., Romanowski K., Johnston J.C. Cardiovascular morbidity and mortality among persons diagnosed with tuberculosis: a systematic review and meta-analysis // PLoS One. – 2020. – Vol. 15. – № 7. – P. e0235821. https://doi.org/10.1371/journal.pone.0235821 pmid:32649721</mixed-citation><mixed-citation xml:lang="en">Basham C.A., Smith S.J., Romanowski K., Johnston J.C. Cardiovascular morbidity and mortality among persons diagnosed with tuberculosis: a systematic review and meta-analysis // PLoS One. – 2020. – Vol. 15. – № 7. – P. e0235821. https://doi.org/10.1371/journal.pone.0235821 pmid:32649721</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Byrne A.L., Marais B.J., Mitnick C.D. et al. Tuberculosis and chronic respiratory disease: a systematic review // Int. J. Infect. Dis. – 2015. – Vol. 32. – P. 138-146. https://www.sciencedirect.com/science/article/pii/S1201971214017330 pmid:25809770</mixed-citation><mixed-citation xml:lang="en">Byrne A.L., Marais B.J., Mitnick C.D. et al. Tuberculosis and chronic respiratory disease: a systematic review // Int. J. Infect. Dis. – 2015. – Vol. 32. – P. 138-146. https://www.sciencedirect.com/science/article/pii/S1201971214017330 pmid:25809770</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Dodd P.J., Yuen C.M., Jayasooriya S.M. et al. Quantifying the global number of tuberculosis survivors: a modelling study // Lancet Infect. Dis. – 2021. – Vol. 21, № 7. – P. 984-992. https://www.sciencedirect.com/science/article/pii/S1473309920309191</mixed-citation><mixed-citation xml:lang="en">Dodd P.J., Yuen C.M., Jayasooriya S.M. et al. Quantifying the global number of tuberculosis survivors: a modelling study // Lancet Infect. Dis. – 2021. – Vol. 21, № 7. – P. 984-992. https://www.sciencedirect.com/science/article/pii/S1473309920309191</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hoger S., Lykens K., Beavers S.F. et al. Longevity loss among cured tuberculosis patients and the potential value of prevention // Int. J. Tuberc. Lung Dis. – 2014. – Vol. 18, № 11. – P. 1347-1352. https://pubmed.ncbi.nlm.nih.gov/25299869 pmid:25299869</mixed-citation><mixed-citation xml:lang="en">Hoger S., Lykens K., Beavers S.F. et al. Longevity loss among cured tuberculosis patients and the potential value of prevention // Int. J. Tuberc. Lung Dis. – 2014. – Vol. 18, № 11. – P. 1347-1352. https://pubmed.ncbi.nlm.nih.gov/25299869 pmid:25299869</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Lönnroth K., Jaramillo E., Williams B.G. et al. Drivers of tuberculosis epidemics: the role of risk factors and social determinants // Soc. Sci. Med. – 2009. – Vol. 68, № 12. – P. 2240-2246. https://www.sciencedirect.com/science/article/pii/S0277953609002111</mixed-citation><mixed-citation xml:lang="en">Lönnroth K., Jaramillo E., Williams B.G. et al. Drivers of tuberculosis epidemics: the role of risk factors and social determinants // Soc. Sci. Med. – 2009. – Vol. 68, № 12. – P. 2240-2246. https://www.sciencedirect.com/science/article/pii/S0277953609002111</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Luczynski P., Poulin P., Romanowski K., Johnston J.C. Tuberculosis and risk of cancer: a systematic review and meta-analysis // PLoS One. – 2022. – Vol. 17, № 12. – P. e0278661. doi: 10.1371/journal.pone.0278661</mixed-citation><mixed-citation xml:lang="en">Luczynski P., Poulin P., Romanowski K., Johnston J.C. Tuberculosis and risk of cancer: a systematic review and meta-analysis // PLoS One. – 2022. – Vol. 17, № 12. – P. e0278661. doi: 10.1371/journal.pone.0278661</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">de Martel C., Georges D., Bray F. et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis // Lancet Glob. Heal. – 2020. – Vol. 8, № 2. – P. e180-190. https://doi.org/10.1016/S2214-109X(19)30488-7</mixed-citation><mixed-citation xml:lang="en">de Martel C., Georges D., Bray F. et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis // Lancet Glob. Heal. – 2020. – Vol. 8, № 2. – P. e180-190. https://doi.org/10.1016/S2214-109X(19)30488-7</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Romanowski K., Baumann B., Basham C.A. et al. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis // Lancet Infect. Dis. – 2019. – Vol. 19, № 10. – P. 1129-1137. https://doi.org/10.1016/S1473-3099(19)30309-3</mixed-citation><mixed-citation xml:lang="en">Romanowski K., Baumann B., Basham C.A. et al. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis // Lancet Infect. Dis. – 2019. – Vol. 19, № 10. – P. 1129-1137. https://doi.org/10.1016/S1473-3099(19)30309-3</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Shu C.C., Liao K.M., Chen Y.C. et al. The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse // Sci. Rep. – 2019. – Vol. 9. – P. 11901. https://doi.org/10.1038/s41598-019-48395-8</mixed-citation><mixed-citation xml:lang="en">Shu C.C., Liao K.M., Chen Y.C. et al. The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse // Sci. Rep. – 2019. – Vol. 9. – P. 11901. https://doi.org/10.1038/s41598-019-48395-8</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Uplekar M., Weil D., Lonnroth K. et al. WHO’s new End TB Strategy // Lancet. – 2015. – Vol. 385, № 9979. – P. 1799-1801. https://doi.org/10.1016/S0140-6736(15)60570-0</mixed-citation><mixed-citation xml:lang="en">Uplekar M., Weil D., Lonnroth K. et al. WHO’s new End TB Strategy // Lancet. – 2015. – Vol. 385, № 9979. – P. 1799-1801. https://doi.org/10.1016/S0140-6736(15)60570-0</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Vento S., Lanzafame M. Tuberculosis and cancer: a complex and dangerous liaison // Lancet Oncol. – 2011. – Vol. 12, № 6. – P. 520-522. http://europepmc.org/abstract/MED/21624773</mixed-citation><mixed-citation xml:lang="en">Vento S., Lanzafame M. Tuberculosis and cancer: a complex and dangerous liaison // Lancet Oncol. – 2011. – Vol. 12, № 6. – P. 520-522. http://europepmc.org/abstract/MED/21624773</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. Global tuberculosis report 2024. – 2024. https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2024</mixed-citation><mixed-citation xml:lang="en">World Health Organization. Global tuberculosis report 2024. – 2024. https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2024</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
